Latest News for: shionogi

Edit

Late Breaking at CROI 2025: SCORPIO PEP Phase 3 Trial – Ensitrelvir is the First and Only COVID 19 Oral Antiviral to Demonstrate Prevention of COVID 19 as Post Exposure Prophylaxis (Shionogi Inc)

Public Technologies 12 Mar 2025
Food and Drug Administration (FDA) in 2025 for post-exposure prophylaxis of COVID-19 following contact with an individual who has COVID-19.3 Shionogi plans to continue interacting with regulatory authorities worldwide ... SHIONOGI Website Inquiry Form.
  • 1
×